Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2082282 | 0.83 | HDAC1 (0.54) | ALDH1A1LMNAL3MBTL1KMT2AKDM4E | |
| SCHEMBL6256620 | 0.80 | ALDH1A1 (0.59) | ALDH1A1LMNAL3MBTL1KMT2AKDM4E | |
| SCHEMBL6253451 | 0.79 | KDM4E (0.53) | ALDH1A1LMNAL3MBTL1KMT2AKDM4E | |
| SCHEMBL6254818 | 0.72 | KDM4E (0.58) | ALDH1A1LMNAKMT2AKDM4EPRMT5 | |
| SCHEMBL6253237 | 0.72 | KDM4E (0.51) | ALDH1A1LMNAL3MBTL1KMT2AKDM4E | |
| SCHEMBL8249322 | 0.72 | ALDH1A1 (0.57) | ALDH1A1LMNAKMT2AKDM4E | |
| SCHEMBL6251273 | 0.72 | KMT2A (0.58) | ALDH1A1LMNAKMT2AKDM4EPRMT5 | |
| SCHEMBL10649040 | 0.71 | MAOA (0.59) | ALDH1A1LMNAL3MBTL1KMT2AKDM4E | |
| SCHEMBL7576759 | 0.71 | KDM4E (0.60) | ALDH1A1KMT2AKDM4EPRMT5DHFR | |
| SCHEMBL18995758 | 0.71 | ALDH1A1 (0.60) | ALDH1A1LMNAKMT2AKDM4EDHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613613-B1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORP (US) | 2021-06-02 | — | — | EP | disclosed |
| US-7863293-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| EP-1613613-A4 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC (CA) | 2009-03-25 | — | — | EP | disclosed |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED CORPORATION (CA) | 2008-10-16 | — | — | US | disclosed |
| US-7291631-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1613613-A2 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004091518-A2 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2004-10-28 | — | — | WO | disclosed |
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | ANORMED CORPORATION (CA) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | CXCR4, CXCR1, CXCR3 | ALDH1A1 357/4885LMNA 4525/4885L3MBTL1 2244/4885 |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | CXCR4, CXCR1, CXCR3 | ALDH1A1 424/4885LMNA 4691/4885L3MBTL1 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.